Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 25

Sort by

Sort Order Select

Journal Articles

What to do with minimal residual disease testing in myeloma

Elisabet E. Manasanch

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 137–141.

https://doi.org/10.1182/hematology.2019000080

Published: 2019

Journal Articles

Minimal residual disease and stem cell transplantation outcomes

Jacqueline Cloos, Gert J. Ossenkoppele, Richard Dillon

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 617–625.

https://doi.org/10.1182/hematology.2019000006

Published: 2019

Journal Articles

MRD evaluation of AML in clinical practice: are we there yet?

Sylvie D. Freeman, Christopher S. Hourigan

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 557–569.

https://doi.org/10.1182/hematology.2019000060

Published: 2019

Journal Articles

Molecular profiling and management of mantle cell lymphoma

Jia Ruan

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 30–40.

https://doi.org/10.1182/hematology.2019000011

Published: 2019

Journal Articles

Sequencing of therapies in relapsed follicular lymphoma

Loretta J. Nastoupil, Christopher R. Flowers, John P. Leonard

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 189–193.

https://doi.org/10.1182/asheducation-2018.1.189

Published: 2018

Journal Articles

A brief, but comprehensive, guide to clonal evolution in aplastic anemia

Daria V. Babushok

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 457–466.

https://doi.org/10.1182/asheducation-2018.1.457

Published: 2018

Journal Articles

Role of the microenvironment across histological subtypes of NHL

Karin Tarte

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 610–617.

https://doi.org/10.1182/asheducation-2017.1.610

Published: 2017

Journal Articles

Is molecular remission the goal of multiple myeloma therapy?

Faith E. Davies

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 205–211.

https://doi.org/10.1182/asheducation-2017.1.205

Published: 2017

Journal Articles

New monogenic disorders identify more pathways to neutropenia: from the clinic to next-generation sequencing

Seth J. Corey, Usua Oyarbide

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 172–180.

https://doi.org/10.1182/asheducation-2017.1.172

Published: 2017

Journal Articles

Diagnosing von Willebrand disease: genetic analysis

Anne Goodeve

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 678–682.

https://doi.org/10.1182/asheducation-2016.1.678

Published: 2016

Journal Articles

MRD in AML: does it already guide therapy decision-making?

Gert Ossenkoppele, Gerrit Jan Schuurhuis

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 356–365.

https://doi.org/10.1182/asheducation-2016.1.356

Published: 2016

Journal Articles

Prognostication of chronic lymphocytic leukemia in the era of new agents

Barbara Eichhorst, Michael Hallek

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 149–155.

https://doi.org/10.1182/asheducation-2016.1.149

Published: 2016

Journal Articles

The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP)

Luca Malcovati, Mario Cazzola

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 299–307.

https://doi.org/10.1182/asheducation-2015.1.299

Published: 2015

Journal Articles

Using red blood cell genomics in transfusion medicine

Jill M. Johnsen

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 168–176.

https://doi.org/10.1182/asheducation-2015.1.168

Published: 2015

Journal Articles

Epigenetic targeting and personalized approaches for AML

Gail J. Roboz

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 44–51.

https://doi.org/10.1182/asheducation-2014.1.44

Published: 2014

Journal Articles

The genomic landscape of acute lymphoblastic leukemia in children and young adults

Charles G. Mullighan

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 174–180.

https://doi.org/10.1182/asheducation-2014.1.174

Published: 2014

Journal Articles

Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1 , SF3B1 , and TP53

Clive S. Zent, W. Richard Burack

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 119–124.

https://doi.org/10.1182/asheducation-2014.1.119

Published: 2014

Journal Articles

Detection and management of minimal residual disease in acute lymphoblastic leukemia

Martin Schrappe

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 244–249.

https://doi.org/10.1182/asheducation-2014.1.244

Published: 2014

Journal Articles

Flamethrowers: blood cells and cancer thrombosis risk

Ingrid Pabinger, Florian Posch

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 410–417.

https://doi.org/10.1182/asheducation.V2014.1.410.3884864

Published: 2014

Journal Articles

ABCs of genomics

Stefan K. Bohlander

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 316–323.

https://doi.org/10.1182/asheducation-2013.1.316

Published: 2013

NARROW

What to do with minimal residual disease testing in myeloma

Minimal residual disease and stem cell transplantation outcomes

MRD evaluation of AML in clinical practice: are we there yet?

Molecular profiling and management of mantle cell lymphoma

Sequencing of therapies in relapsed follicular lymphoma

A brief, but comprehensive, guide to clonal evolution in aplastic anemia

Role of the microenvironment across histological subtypes of NHL

Is molecular remission the goal of multiple myeloma therapy?

New monogenic disorders identify more pathways to neutropenia: from the clinic to next-generation sequencing

Diagnosing von Willebrand disease: genetic analysis

MRD in AML: does it already guide therapy decision-making?

Prognostication of chronic lymphocytic leukemia in the era of new agents

The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP)

Using red blood cell genomics in transfusion medicine

Epigenetic targeting and personalized approaches for AML

The genomic landscape of acute lymphoblastic leukemia in children and young adults

Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1 , SF3B1 , and TP53

Detection and management of minimal residual disease in acute lymphoblastic leukemia

Flamethrowers: blood cells and cancer thrombosis risk

ABCs of genomics

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only